In an acute peritonitis model PQ912 inhibits monocyte infiltration, increases eosinophils and enhances resolvin D2, an important lipid mediator which contributes to termination of inflammatory processes
HALLE (SAALE), Germany, 07 September 2016 – Probiodrug AG (Euronext Amsterdam: PBD), a biopharmaceutical company developing novel therapeutic solutions to treat Alzheimer’s disease (AD), today announced new findings for its Glutaminyl Cyclase (QC) inhibitor in an inflammation animal model. Data were generated in collaboration with Ambiotis SAS (Toulouse, France) and will be presented at upcoming scientific conferences.
The effect of the QC inhibitor PQ912 was investigated in a mouse model of inflammation (thioglycollate induced peritonitis) with special focus on its effect on cell infiltration and release of pro-resolving lipid mediators. The effects seen with PQ912 on recruitment of macrophages and eosinophils, and levels of chemokines and lipid mediators, makes QC inhibition attractive for further evaluation as potential anti-inflammatory drug and/or resolution promoting agent.
Data will be summarized as a poster entitled “Glutaminyl cylase (QC) inhibition in a mouse peritonitis model effects eosinophil and macrophage recruitment and levels of resolution molecules” and presented at:
(1) Summer Frontiers Symposium 2016 ‘Systems Biology of Innate Immunity’
7 – 9 September 2016, Nijmegen, The Netherlands
(2) 6th European Workshop on Lipid Mediators, 6EWLM
27 – 30 September 2016, Frankfurt, Germany
Commenting on the announcement, Dr Inge Lues, CDO of Probiodrug said: “The results obtained to elucidate molecular mechanisms underlying inflammatory disease, triggered by the innate immune system, further the concept of an anti-inflammatory component of QC inhibition, which might play a role in various diseases with an inflammatory component.”
Dr Marc Dubourdeau, CEO/CSO of Ambiotis added: “The development of therapeutics that act agonistically on resolutive pathways is a new emerging approach to correctly terminate inflammation and fight chronic status. We are very glad that our research team was able to bring first evidence on the potential of QC inhibitors as pro-resolutive compounds. Results for PQ912 are thus very promising for the field, showing that resolution pharmacology opens an avenue for treatments that act on the endogenous capacity of the body to stop inflammation.”
For more information please contact:
Probiodrug
Dr Konrad Glund, CEO
Email: contact@probiodrug.de
Hume Brophy
Mary Clark, Supriya Mathur, Eva Haas
Tel: +44 (0) 207 862 6475
Email: probiodrug@humebrophy.com
The Trout Group
Tricia Truehart
Tel: +1 646 378-2953
Email: ttruehart@troutgroup.com
Ambiotis SAS
Dr Marc Dubourdeau, CEO/CSO
Email : marc.dubourdeau@ambiotis.com
HALLE (SAALE), Germany, 07 September 2016 – Probiodrug AG (Euronext Amsterdam: PBD), a biopharmaceutical company developing novel therapeutic solutions to treat Alzheimer’s disease (AD), today announced new findings for its Glutaminyl Cyclase (QC) inhibitor in an inflammation animal model. Data were generated in collaboration with Ambiotis SAS (Toulouse, France) and will be presented at upcoming scientific conferences.
The effect of the QC inhibitor PQ912 was investigated in a mouse model of inflammation (thioglycollate induced peritonitis) with special focus on its effect on cell infiltration and release of pro-resolving lipid mediators. The effects seen with PQ912 on recruitment of macrophages and eosinophils, and levels of chemokines and lipid mediators, makes QC inhibition attractive for further evaluation as potential anti-inflammatory drug and/or resolution promoting agent.
Data will be summarized as a poster entitled “Glutaminyl cylase (QC) inhibition in a mouse peritonitis model effects eosinophil and macrophage recruitment and levels of resolution molecules” and presented at:
(1) Summer Frontiers Symposium 2016 ‘Systems Biology of Innate Immunity’
7 – 9 September 2016, Nijmegen, The Netherlands
(2) 6th European Workshop on Lipid Mediators, 6EWLM
27 – 30 September 2016, Frankfurt, Germany
Commenting on the announcement, Dr Inge Lues, CDO of Probiodrug said: “The results obtained to elucidate molecular mechanisms underlying inflammatory disease, triggered by the innate immune system, further the concept of an anti-inflammatory component of QC inhibition, which might play a role in various diseases with an inflammatory component.”
Dr Marc Dubourdeau, CEO/CSO of Ambiotis added: “The development of therapeutics that act agonistically on resolutive pathways is a new emerging approach to correctly terminate inflammation and fight chronic status. We are very glad that our research team was able to bring first evidence on the potential of QC inhibitors as pro-resolutive compounds. Results for PQ912 are thus very promising for the field, showing that resolution pharmacology opens an avenue for treatments that act on the endogenous capacity of the body to stop inflammation.”
For more information please contact:
Probiodrug
Dr Konrad Glund, CEO
Email: contact@probiodrug.de
Hume Brophy
Mary Clark, Supriya Mathur, Eva Haas
Tel: +44 (0) 207 862 6475
Email: probiodrug@humebrophy.com
The Trout Group
Tricia Truehart
Tel: +1 646 378-2953
Email: ttruehart@troutgroup.com
Ambiotis SAS
Dr Marc Dubourdeau, CEO/CSO
Email : marc.dubourdeau@ambiotis.com
